Cerulean cancer news

Cerulean will reduce headcount by 21 (48%) to 23 after lead candidate CRLX101 missed the primary endpoint

Read the full 172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE